Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Multimodal Blood Test Successfully Screens for Advanced CRC, Adenomas

May 8th 2020

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Onvansertib Regimen Shows Early Promise in KRAS-Mutant mCRC

May 7th 2020

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC

May 6th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers

May 5th 2020

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

May 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Encorafenib/Cetuximab Combo Nears EU Approval for BRAF+ mCRC

May 1st 2020

A European panel has recommended approval of encorafenib in combination with cetuximab for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer.

FDA Approves Encorafenib/Cetuximab Combo for BRAF+ mCRC

April 9th 2020

The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.

Pembrolizumab Improves PFS in Frontline MSI-H/dMMR Colorectal Cancer

April 2nd 2020

Frontline pembrolizumab significantly improved progression-free survival versus chemotherapy in patients with microsatellite instability–high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Dr. Raghav on Ongoing Research With Immunotherapy and Targeted Therapy in CRC

April 2nd 2020

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Marshall Reflects on Major Advances in mCRC

April 1st 2020

John L. Marshall, MD, reflects on recent advances in the field of metastatic colorectal cancer and discusses ongoing research efforts in the space.

Management, Etiology of Younger Patients With CRC Require Deeper Understanding

March 31st 2020

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC

March 28th 2020

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

March 27th 2020

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Dr. Mizrahi on Optimal Sequencing in BRAF V600E-Mutant mCRC

March 26th 2020

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

March 26th 2020

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Dr. Nelson on QOL Data From the BEACON CRC Trial in mCRC

March 26th 2020

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

FLASCO Faculty Flesh Out Case Studies in GI Cancers

March 25th 2020

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Dr. Le on the Need for Aggressive Treatment Interventions in Oligometastatic CRC

March 25th 2020

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

Dr. Raghav on Treatment Options in Newly Diagnosed mCRC

March 25th 2020

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Dr. Overman on Second-Line Therapy Options for Colorectal Cancer

March 23rd 2020

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.